AllianceBernstein
AVTX icon

AllianceBernstein’s Avalo Therapeutics AVTX Stock Holding History

AllianceBernstein’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7
Closed -$14K – 3271
2022
Q1 		$14K Hold
7
– – ﹤0.01% 3228
2021
Q4 		$32K Hold
7
– – ﹤0.01% 3259
2021
Q3 		$42K Hold
7
– – ﹤0.01% 3233
2021
Q2 		$62K Buy
7
+1
+17% +$8.38K ﹤0.01% 3269
2021
Q1 		$54K Hold
6
– – ﹤0.01% 3193
2020
Q4 		$47K Hold
6
– – ﹤0.01% 3145
2020
Q3 		$41K Sell
6
-2
-25% -$15K ﹤0.01% 3130
2020
Q2 		$58K Buy
+8
New +$58.1K ﹤0.01% 3150

Other funds holding AVTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein's AVTX Position: Q2 2022 in Review

AllianceBernstein sold out of Avalo Therapeutics (AVTX) in Q2 2022, closing a stake of 7 shares — an estimated $14K sold.

AllianceBernstein first reported a position in AVTX in Q2 2020 and held it in 8 quarters. The position peaked at $62K in Q2 2021. 43 funds tracked by Wall St. Rank hold AVTX as of Q2 2022.

  • AllianceBernstein reported no remaining Avalo Therapeutics position as of Q2 2022 after selling out during the quarter.
  • AllianceBernstein sold 7 Avalo Therapeutics shares in Q2 2022, an estimated $14K.
  • AllianceBernstein first reported a position in Avalo Therapeutics in Q2 2020 and held it in 8 quarters.
  • AllianceBernstein's Avalo Therapeutics position peaked at $62K in Q2 2021.
  • 43 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2022.

Based on AllianceBernstein's 13F filing for Q2 2022, filed 15 Aug 2022.